The Safety and Efficiency of Propranolol as an Initial Treatment for Pediatric Hemangioma

The Safety and Efficiency of Propranolol as an Initial Treatment for Pediatric Hemangioma

The purpose of this study is to determine the safety and efficiency of Propranolol as an initial treatment for pediatric hemangioma.

• Randomized (A group : propranolol, B group : prednisolone)
• A group : 3 days admission and medication for 16 weeks
• B group : medication for 16 weeks without admission
• Hemangioma volume comparison by using MRI
• other measurement and drug adverse reaction monitoring

Inclusion Criteria:

• Hemangioma patient ( 0 ~ 9 months old)
• No treatment before
• 10 ~ 20 % volume increase in 2 ~ 4 weeks
• Hemangioma that caused organ function
• Hemangioma that will cause aesthetic problem

Exclusion Criteria:

• Cardiovascular disease (impossible to use propranolol)
• Drug adverse reaction or allergy history (propranolol, steroid)
• Bradycardia, Atrioventricular block, atrial block
• Cardiogenic Shock
• Right heart failure (pulmonary hypertension)
• Congestive heart failure
• Hypotension
• Peripheral nerve disease (moderate)
• Angina
• Hormone deficiency patient
• Pulmonary disease (asthma)
• diabetic ketoacidosis
• laser treatment history